胃食道逆流症（GERD）の世界市場レポート 2025年

胃食道逆流症（GERD）の市場規模は、今後数年間で安定した成長が見込まれます。2029年にはCAGR2.7％で59億4,000万米ドルに成長します。予測期間の成長は、人口の高齢化、ヘルスケア支出の増加、バイオマーカーの出現、消化管疾患のスクリーニングプログラムの増加、胸焼けの有病率の増加、医療機器需要の増加などに起因しています。予測期間における主な動向には、診断の進歩、外科手術の進歩、標的療法の開発、遠隔医療サービスの採用などがあります。

アルコール消費の高い発生率が胃食道逆流症（GERD）市場の成長を促進すると予想されます。アルコール摂取はエタノールを含む飲料の摂取を意味し、過剰に摂取すると食道運動を低下させ、食道の圧力レベルを低下させることによってGERDの開発に寄与する可能性があります。例えば、2024年7月、英国の機関である下院図書館は、2022年にイングランドの成人の56％が過去1週間にアルコールを摂取していたと報告しました。このデータから飲酒習慣の男女差が明らかになり、この期間にアルコールを摂取したことがあるのは男性が61％、女性が51％でした。その結果、飲酒習慣の増加がGERD市場の成長に拍車をかけています。

胃食道逆流症（GERD）市場で事業を展開する有力企業は、GERDに対する革新的な治療デバイスの導入に注力し、市場でのリーダーシップの維持を目指しています。例えば、米国の医療技術企業Laborie Medical Technologiesは2023年4月、胃食道逆流症（GERD）の診断に特化したワイヤレスpHカプセル型逆流検査診断システムalpHaONEを発表しました。この先進的なシステムは、最大96時間の包括的なモニタリングデータを提供することができます。特に、便利な拡大ボタンと信頼性の高いカプセル供給システムを備えたコンパクトで使いやすいデザインが自慢です。さらに、バーチャル指示プログラムを備えた専用ソフトウェア・アプリケーションや、ユーザーが症状ボタンをカスタマイズできるオプションも備えており、全体的なユーザー体験を向上させています。この革新的なアプローチは、GERD治療市場の進化に大きな影響を与えています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界胃食道逆流症（GERD） PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の胃食道逆流症（GERD）市場：成長率分析
• 世界の胃食道逆流症（GERD）市場の実績：規模と成長, 2019-2024
• 世界の胃食道逆流症（GERD）市場の予測：規模と成長, 2024-2029, 2034F
• 世界胃食道逆流症（GERD）総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の胃食道逆流症（GERD）市場薬の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• プロトンポンプ阻害剤
• H2受容体遮断薬
• プロキネティックエージェント
• ドーパミン受容体拮抗薬
• エンドシンチ
• ストレッタ
• エソフィエックス
• 経口切開なし噴門形成術（TIF）
• 世界の胃食道逆流症（GERD）市場手順別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 侵襲的
• 低侵襲
• 世界の胃食道逆流症（GERD）市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• ホームケア
• 専門クリニック
• 世界の胃食道逆流症（GERD）市場制酸剤の種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• 炭酸カルシウム
• 水酸化マグネシウム
• 水酸化アルミニウム
• 世界の胃食道逆流症（GERD）市場プロトンポンプ阻害剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• オメプラゾール
• エソメプラゾール
• ランソプラゾール
• パントプラゾール
• ラベプラゾール
• 世界の胃食道逆流症（GERD）市場H2受容体遮断薬の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ラニチジン
• ファモチジン
• ニザチジン
• シメチジン
• 世界の胃食道逆流症（GERD）市場、消化管運動促進薬のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• メトクロプラミド
• ドンペリドン
• 世界の胃食道逆流症（GERD）市場、ドーパミン受容体拮抗薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• プロクロルペラジン
• ドロペリドール
• 世界の胃食道逆流症（GERD）市場、EndoCinchのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 内視鏡縫合システム
• 世界の胃食道逆流症（GERD）市場、Strettaのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 高周波アブレーションシステム
• 世界の胃食道逆流症（GERD）市場、EsophyXのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口噴門形成術システム
• 世界の胃食道逆流症（GERD）市場、経口切開なし噴門形成術（TIF）のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• TIFデバイスとシステム

第7章 地域別・国別分析

• 世界の胃食道逆流症（GERD）市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の胃食道逆流症（GERD）市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 胃食道逆流症（GERD）市場：競合情勢
• 胃食道逆流症（GERD）市場：企業プロファイル
  • GlaxoSmithKline PLC Overview, Products and Services, Strategy and Financial Analysis
  • SRS Life Sciences Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca Plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Reckitt Benckiser Group Plc
• Eisai Co. Ltd.
• Pfizer Inc.
• Medtronic Plc
• Teva Pharmaceuticals
• HK inno.N Corporation
• Sebela Pharmaceuticals
• Mylan N.V.
• Bausch Health Companies Inc.
• Johnson & Johnson MedTech
• Eisai Co. Ltd.
• Sun Pharmaceutical Industries Ltd.
• Perrigo Company PLC
• Dr. Reddy's Laboratories Ltd.
• Aurobindo Pharma Limited

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 胃食道逆流症（GERD）市場2029：新たな機会を提供する国
• 胃食道逆流症（GERD）市場2029：新たな機会を提供するセグメント
• 胃食道逆流症（GERD）市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Gastroesophageal reflux disease (GERD) is a condition characterized by the regurgitation of stomach acid into the esophagus, leading to irritation and discomfort. Treating GERD involves employing a range of medical strategies and interventions to effectively manage its symptoms and associated complications.

The primary drug categories used in the treatment of gastroesophageal reflux disease include antacids, proton pump inhibitors, H2 receptor blockers, prokinetic agents, dopamine receptor antagonists, and minimally invasive procedures such as EndoCinch, Stretta, Asphyx, and Transoral Incisionless Fundoplication (TIF). Antacids, for instance, function by neutralizing stomach acid, thus increasing the stomach's pH level to alleviate symptoms. Additionally, these treatment approaches can be divided into invasive and minimally invasive procedures, offering options that cater to the unique needs of patients. These therapies are made available through various healthcare providers, including hospitals, homecare services, and specialty clinics.

The gastroesophageal reflux disease (GERD) market research report is one of a series of new reports from The Business Research Company that provides gastroesophageal reflux disease (GERD) market statistics, including gastroesophageal reflux disease (GERD) industry global market size, regional shares, competitors with a gastroesophageal reflux disease (GERD) market share, detailed gastroesophageal reflux disease (GERD) market segments, market trends and opportunities and any further data you may need to thrive in the gastroesophageal reflux disease (GERD) industry. This gastroesophageal reflux disease (GERD) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The gastroesophageal reflux disease (GERD) market size has grown marginally in recent years. It will grow from $5.25 billion in 2024 to $5.35 billion in 2025 at a compound annual growth rate (CAGR) of 2.0%. The growth in the historic period can be attributed to lifestyle and dietary changes, obesity epidemic, growing awareness about gerd treatment, globalization of pharmaceutical industry, investments for gerd treatments.

The gastroesophageal reflux disease (GERD) market size is expected to see steady growth in the next few years. It will grow to $5.94 billion in 2029 at a compound annual growth rate (CAGR) of 2.7%. The growth in the forecast period can be attributed to aging population, rising healthcare spending, emergence of biomarker, growing number of screening programs for gerd, increasing prevalence of heartburn, increased demand for medical equipment. Major trends in the forecast period include diagnostic advancements, surgical advancements, development of targeted therapies, adoption of telehealth services.

The high incidence of alcohol consumption is expected to drive the growth of the gastroesophageal reflux disease (GERD) market. Alcohol consumption refers to the ingestion of beverages containing ethanol, which, when consumed in excess, can contribute to the development of GERD by reducing esophageal motility and lowering the pressure levels in the esophagus. For example, in July 2024, the House of Commons Library, a UK-based institution, reported that in 2022, 56% of adults in England had consumed alcohol in the past week. This data revealed a gender difference in drinking habits, with 61% of men and 51% of women having consumed alcohol during this period. Consequently, the increasing prevalence of alcohol consumption is fueling the growth of the GERD market.

Prominent companies operating in the gastroesophageal reflux disease (GERD) market are dedicated to the introduction of innovative treatment devices for GERD, aimed at maintaining their market leadership. For example, in April 2023, Laborie Medical Technologies, a US-based medical technology firm, unveiled the alpHaONE wireless pH-capsule reflux testing diagnostic system, designed specifically for the diagnosis of gastroesophageal reflux disease (GERD). This advanced system is capable of providing up to 96 hours of comprehensive monitoring data. Notably, it boasts a compact and user-friendly design with conveniently enlarged buttons and a dependable capsule delivery system. Moreover, it features a dedicated software application equipped with a virtual instruction program and the option for users to customize symptom buttons, thereby enhancing the overall user experience. This innovative approach is significantly impacting the evolution of the GERD treatment market.

In October 2022, Sebela Pharmaceuticals Inc., a US-based pharmaceutical company specializing in the production of gastroesophageal reflux disease medications, established a strategic partnership with HK Inno.N Corporation, a South Korea-based pharmaceutical company, in an arrangement involving an undisclosed sum. This collaboration is aimed at jointly developing and launching tegoprazan, a pioneering potassium-competitive acid blocker (P-CAB), within the US and Canada. Tegoprazan, already authorized and available in South Korea and China, holds significant promise as an innovative addition to Sebela Pharmaceuticals' gastroenterology product line, catering to individuals dealing with gastroesophageal reflux disease.

Major companies operating in the gastroesophageal reflux disease (GERD) market are GlaxoSmithKline PLC, SRS Life Sciences, Johnson & Johnson Services Inc., Takeda Pharmaceutical Company Limited, AstraZeneca PLC, Reckitt Benckiser Group PLC, Eisai Co. Ltd., Pfizer Inc., Medtronic PLC, Teva Pharmaceuticals, HK inno.N Corporation, Sebela Pharmaceuticals, Mylan N.V., Bausch Health Companies Inc., Johnson & Johnson MedTech, Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Perrigo Company PLC, Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Ferring B.V., Amneal Pharmaceuticals LLC, Zydus Lifesciences Ltd., Lupin Limited, Torrent Pharmaceuticals Ltd., Salix Pharmaceuticals Inc., Almirall S.A., HK inno.N Corporation, SRS Life Sciences Pte. Ltd.

North America was the largest region in the gastroesophageal reflux disease (GERD) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in gastroesophageal reflux disease (GERD) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the gastroesophageal reflux disease (GERD) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The gastroesophageal reflux disease (GERD) market consists of revenues earned by entities by providing pharmaceutical therapies, surgical procedures and diagnostic tests. The market value includes the value of related goods sold by the service provider or included within the service offering. The gastroesophageal reflux disease (GERD) market also includes sales of gamma-aminobutyric acid type B receptor agonists and alginate antacids. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Gastroesophageal Reflux Disease (GERD) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on gastroesophageal reflux disease (gerd) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for gastroesophageal reflux disease (gerd) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The gastroesophageal reflux disease (gerd) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Antacids; Proton Pump Inhibitors; H2 Receptor Blocker; Pro Kinetic Agents; Dopamine Receptor Antagonist; EndoCinch; Stretta; EsophyX; Transoral Incisionless Fundoplication (TIF)
• 2) By Procedure: Invasive; Minimally Invasive
• 3) By End-Users: Hospital; Homecare; Specialty Clinics
• Subsegments:
• 1) By Antacids: Calcium Carbonate; Magnesium Hydroxide; Aluminum Hydroxide
• 2) By Proton Pump Inhibitors: Omeprazole; Esomeprazole; Lansoprazole; Pantoprazole; Rabeprazole
• 3) By H2 Receptor Blockers: Ranitidine; Famotidine; Nizatidine; Cimetidine
• 4) By Prokinetic Agents: Metoclopramide; Domperidone
• 5) By Dopamine Receptor Antagonists: Prochlorperazine; Droperidol
• 6) By EndoCinch: Endoscopic Suturing Systems
• 7) By Stretta: Radiofrequency Ablation Systems
• 8) By EsophyX: Transoral Fundoplication Systems
• 9) By Transoral Incisionless Fundoplication (TIF): TIF Devices And Systems
• Companies Mentioned: GlaxoSmithKline PLC; SRS Life Sciences; Johnson & Johnson Services Inc.; Takeda Pharmaceutical Company Limited; AstraZeneca Plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Gastroesophageal Reflux Disease (GERD) Market Characteristics

3. Gastroesophageal Reflux Disease (GERD) Market Trends And Strategies

4. Gastroesophageal Reflux Disease (GERD) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Gastroesophageal Reflux Disease (GERD) Growth Analysis And Strategic Analysis Framework

• 5.1. Global Gastroesophageal Reflux Disease (GERD) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Gastroesophageal Reflux Disease (GERD) Market Growth Rate Analysis
• 5.4. Global Gastroesophageal Reflux Disease (GERD) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Gastroesophageal Reflux Disease (GERD) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Gastroesophageal Reflux Disease (GERD) Total Addressable Market (TAM)

6. Gastroesophageal Reflux Disease (GERD) Market Segmentation

• 6.1. Global Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Proton Pump Inhibitors
• H2 Receptor Blocker
• Pro Kinetic Agents
• Dopamine Receptor Antagonist
• EndoCinch
• Stretta
• EsophyX
• Transoral Incisionless Fundoplication (TIF)
• 6.2. Global Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Invasive
• Minimally Invasive
• 6.3. Global Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital
• Homecare
• Specialty Clinics
• 6.4. Global Gastroesophageal Reflux Disease (GERD) Market, Sub-Segmentation Of Antacids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Calcium Carbonate
• Magnesium Hydroxide
• Aluminum Hydroxide
• 6.5. Global Gastroesophageal Reflux Disease (GERD) Market, Sub-Segmentation Of Proton Pump Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Omeprazole
• Esomeprazole
• Lansoprazole
• Pantoprazole
• Rabeprazole
• 6.6. Global Gastroesophageal Reflux Disease (GERD) Market, Sub-Segmentation Of H2 Receptor Blockers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ranitidine
• Famotidine
• Nizatidine
• Cimetidine
• 6.7. Global Gastroesophageal Reflux Disease (GERD) Market, Sub-Segmentation Of Prokinetic Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Metoclopramide
• Domperidone
• 6.8. Global Gastroesophageal Reflux Disease (GERD) Market, Sub-Segmentation Of Dopamine Receptor Antagonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Prochlorperazine
• Droperidol
• 6.9. Global Gastroesophageal Reflux Disease (GERD) Market, Sub-Segmentation Of EndoCinch, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Endoscopic Suturing Systems
• 6.10. Global Gastroesophageal Reflux Disease (GERD) Market, Sub-Segmentation Of Stretta, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Radiofrequency Ablation Systems
• 6.11. Global Gastroesophageal Reflux Disease (GERD) Market, Sub-Segmentation Of EsophyX, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Transoral Fundoplication Systems
• 6.12. Global Gastroesophageal Reflux Disease (GERD) Market, Sub-Segmentation Of Transoral Incisionless Fundoplication (TIF), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• TIF Devices And Systems

7. Gastroesophageal Reflux Disease (GERD) Market Regional And Country Analysis

• 7.1. Global Gastroesophageal Reflux Disease (GERD) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Gastroesophageal Reflux Disease (GERD) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Gastroesophageal Reflux Disease (GERD) Market

• 8.1. Asia-Pacific Gastroesophageal Reflux Disease (GERD) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Gastroesophageal Reflux Disease (GERD) Market

• 9.1. China Gastroesophageal Reflux Disease (GERD) Market Overview
• 9.2. China Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Gastroesophageal Reflux Disease (GERD) Market

• 10.1. India Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Gastroesophageal Reflux Disease (GERD) Market

• 11.1. Japan Gastroesophageal Reflux Disease (GERD) Market Overview
• 11.2. Japan Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Gastroesophageal Reflux Disease (GERD) Market

• 12.1. Australia Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Gastroesophageal Reflux Disease (GERD) Market

• 13.1. Indonesia Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Gastroesophageal Reflux Disease (GERD) Market

• 14.1. South Korea Gastroesophageal Reflux Disease (GERD) Market Overview
• 14.2. South Korea Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Gastroesophageal Reflux Disease (GERD) Market

• 15.1. Western Europe Gastroesophageal Reflux Disease (GERD) Market Overview
• 15.2. Western Europe Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Gastroesophageal Reflux Disease (GERD) Market

• 16.1. UK Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Gastroesophageal Reflux Disease (GERD) Market

• 17.1. Germany Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Gastroesophageal Reflux Disease (GERD) Market

• 18.1. France Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Gastroesophageal Reflux Disease (GERD) Market

• 19.1. Italy Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Gastroesophageal Reflux Disease (GERD) Market

• 20.1. Spain Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Gastroesophageal Reflux Disease (GERD) Market

• 21.1. Eastern Europe Gastroesophageal Reflux Disease (GERD) Market Overview
• 21.2. Eastern Europe Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Gastroesophageal Reflux Disease (GERD) Market

• 22.1. Russia Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Gastroesophageal Reflux Disease (GERD) Market

• 23.1. North America Gastroesophageal Reflux Disease (GERD) Market Overview
• 23.2. North America Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Gastroesophageal Reflux Disease (GERD) Market

• 24.1. USA Gastroesophageal Reflux Disease (GERD) Market Overview
• 24.2. USA Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Gastroesophageal Reflux Disease (GERD) Market

• 25.1. Canada Gastroesophageal Reflux Disease (GERD) Market Overview
• 25.2. Canada Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Gastroesophageal Reflux Disease (GERD) Market

• 26.1. South America Gastroesophageal Reflux Disease (GERD) Market Overview
• 26.2. South America Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Gastroesophageal Reflux Disease (GERD) Market

• 27.1. Brazil Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Gastroesophageal Reflux Disease (GERD) Market

• 28.1. Middle East Gastroesophageal Reflux Disease (GERD) Market Overview
• 28.2. Middle East Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Gastroesophageal Reflux Disease (GERD) Market

• 29.1. Africa Gastroesophageal Reflux Disease (GERD) Market Overview
• 29.2. Africa Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Gastroesophageal Reflux Disease (GERD) Market Competitive Landscape And Company Profiles

• 30.1. Gastroesophageal Reflux Disease (GERD) Market Competitive Landscape
• 30.2. Gastroesophageal Reflux Disease (GERD) Market Company Profiles
  • 30.2.1. GlaxoSmithKline PLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. SRS Life Sciences Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AstraZeneca Plc Overview, Products and Services, Strategy and Financial Analysis

31. Gastroesophageal Reflux Disease (GERD) Market Other Major And Innovative Companies

• 31.1. Reckitt Benckiser Group Plc
• 31.2. Eisai Co. Ltd.
• 31.3. Pfizer Inc.
• 31.4. Medtronic Plc
• 31.5. Teva Pharmaceuticals
• 31.6. HK inno.N Corporation
• 31.7. Sebela Pharmaceuticals
• 31.8. Mylan N.V.
• 31.9. Bausch Health Companies Inc.
• 31.10. Johnson & Johnson MedTech
• 31.11. Eisai Co. Ltd.
• 31.12. Sun Pharmaceutical Industries Ltd.
• 31.13. Perrigo Company PLC
• 31.14. Dr. Reddy's Laboratories Ltd.
• 31.15. Aurobindo Pharma Limited

32. Global Gastroesophageal Reflux Disease (GERD) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Gastroesophageal Reflux Disease (GERD) Market

34. Recent Developments In The Gastroesophageal Reflux Disease (GERD) Market

35. Gastroesophageal Reflux Disease (GERD) Market High Potential Countries, Segments and Strategies

• 35.1 Gastroesophageal Reflux Disease (GERD) Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Gastroesophageal Reflux Disease (GERD) Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Gastroesophageal Reflux Disease (GERD) Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer